As a result, LKB1-intact NSCLC tumors could be sensitized to anti-PD-1 antibodies with metformin whereas no obvious suppression from metformin was observed in LKB1-deficient tumors [144]. Here, STK11 is linked to non-small cell lung carcinoma.